Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1974 Jan;9(1):53-9.
doi: 10.1128/iai.9.1.53-59.1974.

Relationship of pre-existing antibody to subsequent infection by Mycoplasma pneumoniae in adults

Relationship of pre-existing antibody to subsequent infection by Mycoplasma pneumoniae in adults

D P McCormick et al. Infect Immun. 1974 Jan.

Abstract

An extensive study of the epidemiological and serological characteristics of Mycoplasma pneumoniae infection was carried out in a military population. There was an increase in the infection rate at Camp Lejeune during the summer months as indicated by a relative increase in isolations, seroconversions, and hospitalizations for M. pneumoniae pneumonia. Twenty-three percent of the trainees who later became infected had detectable, pre-existing antilipid antibody to M. pneumoniae. When the whole organism was used as antigen, a pre-existing complement fixation (CF) titer of 1:4 or greater correlated with resistance to M. pneumoniae disease as defined by the absence of a fourfold rise in CF antibody, shedding of organisms, and clinical illness. Pre-existing antilipid fraction CF antibody titers of 1:16 or greater correlated with protection against mild and severe M. pneumoniae disease. Antilipid CF antibody titers of 1:4 and 1:8 were related to protection against mild disease but were not associated with protection against pneumonia which required hospitalization. The severity of illness was directly related to the CF antibody response in trainees with acute respiratory disease and pneumonia due to M. pneumoniae. The findings provide a basis for the development of a M. pneumoniae vaccine.

PubMed Disclaimer

References

    1. Acta Pathol Microbiol Scand. 1967;71(2):265-73 - PubMed
    1. JAMA. 1961 Jan 21;175:213-20 - PubMed
    1. Mil Med. 1971 Dec;136(12):873-80 - PubMed
    1. Am J Epidemiol. 1969 Apr;89(4):405-21 - PubMed
    1. Proc Soc Exp Biol Med. 1966 Jul;122(3):786-90 - PubMed

LinkOut - more resources